Alector (NASDAQ:ALEC) Announces Earnings Results, Beats Expectations By $0.03 EPS

Alector (NASDAQ:ALEC) issued its quarterly earnings results on Tuesday. The company reported ($0.45) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.03, MarketWatch Earnings reports. Alector had a negative return on equity of 58.27% and a negative net margin of 378.57%.

Shares of Alector stock opened at $24.40 on Wednesday. The business’s fifty day simple moving average is $28.65 and its 200 day simple moving average is $20.77. The firm has a market capitalization of $1.64 billion and a P/E ratio of -8.94. Alector has a 12 month low of $13.64 and a 12 month high of $35.93. The company has a current ratio of 6.57, a quick ratio of 6.56 and a debt-to-equity ratio of 0.19.

In other Alector news, VP Calvin Yu sold 63,541 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $30.04, for a total value of $1,908,771.64. Following the sale, the vice president now directly owns 188,835 shares in the company, valued at $5,672,603.40. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Orbimed Advisors Llc sold 379,997 shares of the business’s stock in a transaction on Thursday, January 9th. The shares were sold at an average price of $19.50, for a total value of $7,409,941.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 519,969 shares of company stock worth $11,210,167. Corporate insiders own 34.40% of the company’s stock.

A number of analysts recently commented on ALEC shares. Zacks Investment Research upgraded Alector from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a report on Tuesday, March 17th. Stifel Nicolaus started coverage on Alector in a report on Tuesday, February 18th. They set a “buy” rating on the stock. BTIG Research started coverage on Alector in a report on Wednesday, November 27th. They set a “buy” rating and a $28.00 price target on the stock. ValuEngine upgraded Alector from a “sell” rating to a “hold” rating in a report on Tuesday, March 3rd. Finally, Cowen reiterated a “buy” rating on shares of Alector in a report on Monday, December 16th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $27.00.

Alector Company Profile

Alector, Inc, a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease.

Further Reading: What is a Swap?

Earnings History for Alector (NASDAQ:ALEC)

Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.